Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.41 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.41 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016839 | 0.88 | SYK (0.57) | HTTSYKSMN1; SMN2LMNAMAPT | |
| SCHEMBL9203498 | 0.86 | HTT (0.56) | HTTSYKSMN1; SMN2LMNAMAPT | |
| SCHEMBL10663962 | 0.86 | HTT (0.56) | HTTSYKSMN1; SMN2LMNAMAPT | |
| SCHEMBL4339879 | 0.84 | HTT (0.63) | HTTSMN1; SMN2LMNAMAPTCTSL | |
| SCHEMBL25196389 | 0.84 | SYK (0.45) | HTTSYKSMN1; SMN2LMNAMAPT | |
| SCHEMBL17495253 | 0.83 | HTT (0.56) | HTTSYKSMN1; SMN2LMNAMAPT | |
| SCHEMBL25908037 | 0.83 | ALDH1A1 (0.53) | HTTSYKSMN1; SMN2LMNAMAPT | |
| SCHEMBL6932926 | 0.83 | ALDH1A1 (0.53) | HTTSYKSMN1; SMN2LMNAMAPT | |
| SCHEMBL557536 | 0.83 | ALDH1A1 (0.46) | SYKMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL7907133 | 0.82 | SYK (0.62) | HTTSYKSMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275727-A1 | Peptide turn mimetics | MIMETICA PTY LIMITED (AU) | 2009-11-05 | — | — | US | disclosed |
| US-20090275727-A1 | Peptide turn mimetics | MIMETICA PTY LIMITED (AU) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275727-A1 | Peptide turn mimetics | IAPP, GLP1R, VIP | HTT 705/4885SYK 3770/4885SMN1; SMN2 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.